This company is no longer actively trading as an independent public company (delisted, acquired, or ceased operations). This profile is retained for reference.
Tryp Therapeutics is a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.
Stock Performance
Tryp Therapeutics News 29 articles
- Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited
- James Gilligan is Leading the Next Wave of Psilocybin – Podcast Episode #35
- Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital
- Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy
- Tryp Therapeutics and Massachusetts General Hospital Sign Letter of Intent for Clinical Study Investigating the Use of Psilocybin-Assisted Psychotherapy for the Treatment of Patients Suffering From Irritable Bowel Syndrome (IBS)
- Tryp Therapeutics Announces Fiscal Year 2022 Financial Results and Reports Corporate Highlights
- Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference
- Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin
- Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803
- Tryp Therapeutics Appoints Jim O’Neill as Chief Financial Officer
- Tryp Therapeutics Retains IMS Investor Relations
- Tryp Therapeutics Announces Results of First Patient Dosed in Phase II Clinical Trial for Binge Eating Disorder
- Tryp Therapeutics Announces $2,000,000 Financing and Changes in Management, Board of Directors
- Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder
- Tryp Therapeutics Announces Fiscal Year 2021 Financial Results and Reports on Corporate Highlights
- Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia
- Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders
- Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia
- Tryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETF
- Tryp Therapeutics To Collaborate With Researchers at The University of Wisconsin-Madison
- Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida
- Tryp Therapeutics to Present at Canaccord Genuity Annual Growth Conference
- Tryp Therapeutics Announces Q3 2021 Financial Results
- Tryp Therapeutics Partners with Alcami for Proprietary Formulations
- Tryp Therapeutics Announces Patent Filing For Improved Administration of Psychedelics
- Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller
- Tryp Therapeutics Goes Public; Here’s Everything You Need to Know
- Tryp Therapeutics Completes Initial Public Offering
- Tryp Therapeutics Files Final Prospectus and Announces Initial Public Offering